These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


236 related items for PubMed ID: 7683442

  • 21. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S, LeBoeuf RD, Blalock JE.
    Proc Natl Acad Sci U S A; 1993 Sep 15; 90(18):8747-51. PubMed ID: 8378359
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Neonatal tolerance to an immunodominant T cell reactivity does not confer resistance to EAMG induction in Lewis rats.
    Zoda TE, Brandon K, Krolick KA.
    J Neuroimmunol; 1995 Mar 15; 57(1-2):35-44. PubMed ID: 7535790
    [Abstract] [Full Text] [Related]

  • 25. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
    Bionda A, De Baets MH, Tzartos SJ, Lindstrom JM, Weigle WO, Theophilopoulos AN.
    Clin Exp Immunol; 1984 Jul 15; 57(1):41-50. PubMed ID: 6611231
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antigen presentation and T cell specificity repertoire in determining responsiveness to an epitope important in experimental autoimmune myasthenia gravis.
    Zoda TE, Krolick KA.
    J Neuroimmunol; 1993 Mar 15; 43(1-2):131-8. PubMed ID: 7681444
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB, Shi FD, Li H, van der Meide PH, Ljunggren HG, Link H.
    Clin Immunol; 2000 May 15; 95(2):156-62. PubMed ID: 10779409
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. T-cell vaccination in experimental myasthenia gravis: a double-edged sword.
    Kahn CR, McIntosh KR, Drachman DB.
    J Autoimmun; 1990 Dec 15; 3(6):659-69. PubMed ID: 2150910
    [Abstract] [Full Text] [Related]

  • 32. Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides.
    Souroujon MC, Carmon S, Fuchs S.
    Immunol Lett; 1992 Sep 15; 34(1):19-25. PubMed ID: 1282497
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis.
    Dedhia V, Goluszko E, Wu B, Deng C, Christadoss P.
    Clin Immunol Immunopathol; 1998 Jun 15; 87(3):266-75. PubMed ID: 9646836
    [Abstract] [Full Text] [Related]

  • 35. Lymphocyte responsiveness to acetylcholine receptor in rats with experimental autoimmune myasthenia gravis.
    Noguchi SA, Drachman DB, Adams RN, Hirsch RL.
    Ann Neurol; 1980 Jul 15; 8(1):32-7. PubMed ID: 7406445
    [Abstract] [Full Text] [Related]

  • 36. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes.
    Spack EG, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma SD.
    J Autoimmun; 1995 Dec 15; 8(6):787-807. PubMed ID: 8824707
    [Abstract] [Full Text] [Related]

  • 37. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
    Wang ZY, Qiao J, Link H.
    J Neuroimmunol; 1993 May 15; 44(2):209-14. PubMed ID: 8505410
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.